HPLC method for the determination of penciclovir in human plasma and application to a bioequivalence study.
暂无分享,去创建一个
Xingjie Guo | Xinxing Gao | N. Guo | Junming Li | Yongyu Pan
[1] Ji-Hyung Seo,et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[2] Y. Daali,et al. Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[3] K. H. Kim,et al. Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir. , 1999, Bioorganic & medicinal chemistry.
[4] B. Korba,et al. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells , 1996, Antimicrobial agents and chemotherapy.
[5] R. Hannah,et al. Comparison of high-performance liquid chromatography and capillary zone electrophoresis in penciclovir biodegradation kinetic studies. , 1995, Journal of chromatography. B, Biomedical applications.
[6] C. Filer,et al. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[7] W. Prince,et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. , 1994, The Journal of antimicrobial chemotherapy.
[8] L. Benet,et al. Pharmacokinetics of Famciclovir in Man , 1993 .
[9] D. Sutton,et al. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16 , 1993, Antimicrobial Agents and Chemotherapy.
[10] D. Sutton,et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir] , 1989, Antimicrobial Agents and Chemotherapy.
[11] D. Sutton,et al. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. , 1989, Journal of medicinal chemistry.
[12] R. Hodge,et al. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells , 1989, Antimicrobial Agents and Chemotherapy.
[13] D. Pierce,et al. High-performance liquid chromatographic method for the determination of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL-39123) in human plasma and urine. , 1989, The Analyst.
[14] D. Sutton,et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals , 1988, Antimicrobial Agents and Chemotherapy.
[15] D. Sutton,et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture , 1987, Antimicrobial Agents and Chemotherapy.